Robert Alter

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil et al. · The Lancet · 2019 · 3.2K citations · Full text

Medicine, Oncology, Cancer Pharmacology +11

Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab

Stuart L. Goldberg, Andrew L. Pecora, Robert Alter et al. · Blood · 2002 · 190 citations · Full text

Medicine, Hematology, Infectious Diseases +17

Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study

Robert J. Motzer, Camillo Porta, Masatoshi Eto et al. · Journal of Clinical Oncology · 2024 · 158 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial

Scott S. Tykodi, Lucio Gordan, Robert Alter et al. · Journal for ImmunoTherapy of Cancer · 2022 · 138 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer

Matthew D. Galsky, Amir Mortazavi, Matthew I. Milowsky et al. · Journal of Clinical Oncology · 2020 · 133 citations · Full text

Medicine, Oncology, Pharmacology +7